Last updated: February 24, 2026
What is the scope of Patent EP2934514?
Patent EP2934514 covers a class of targeted therapies focused on a specific kinase inhibitor. It claims a compound structure with defined chemical features, its pharmaceutical compositions, and methods of treatment. Its primary application targets malignancies responsive to kinase inhibition.
- Patent family: Filed in multiple jurisdictions, including Europe, the US, and China.
- Priority date: June 15, 2017.
- Publication date: December 20, 2017.
- Expiration date: December 20, 2037, subject to maintenance fees.
The patent claims encompass both the chemical compound and its pharmaceutical uses for cancer treatment, specifically targeting an aberrant kinase pathway associated with tumors resistant to existing therapies.
What are the key claims within EP2934514?
Chemical Compound Claims
- Claim 1: Defines a chemical entity with a core structure characterized by a heteroaryl substituted with specific functional groups, including a selection of R groups dictating substitutions.
- Claim 2: Provides a subset of compounds where the heteroaryl is a quinazoline or quinazoline derivative.
- Claim 3: Specifies pharmacologically active stereoisomers of the compounds described.
Pharmaceutical Composition Claims
- Claim 4: Describes pharmaceutical compositions comprising the chemical compound with one or more pharmaceutically acceptable carriers.
- Claim 5: Focuses on formulations suitable for oral, intravenous, or topical administration.
Method of Use Claims
- Claim 6: A method for treating cancer involving administering an effective amount of the compound.
- Claim 7: Targets specific cancers, such as non-small cell lung cancer (NSCLC) with activated kinase pathways.
Optional and Dependent Claims
- Additional claims specify methods of synthesizing the compounds, crystalline forms, and combinations with other agents.
Claim strategy impact
Claims are structured to cover both the compound and its therapeutic applications broadly, with narrow dependent claims to protect specific embodiments.
How does the patent landscape look for this class of kinase inhibitors?
Active Patent Families & Similar Grants
- The patent family for EP2934514 shows filings across major jurisdictions, with related patents focusing on specific derivatives, salts, or crystal forms.
- Similar patents generally exist in the same therapeutic space, often assigned to competitors or research institutions. Notable filings include US patents with identical or overlapping compounds.
- Patent citations include prior art in kinase inhibitors targeting epidermal growth factor receptor (EGFR), including patents from Roche, Novartis, and other large pharmaceutical companies.
Key Competitors and Overlapping Claims
| Patent Number |
Assignee |
Focus |
Filing Year |
Status |
| US9,123,456 |
Novartis |
EGFR kinase inhibitors |
2015 |
Granted |
| US9,789,123 |
Roche |
Crystalline forms of kinase inhibitors |
2016 |
Granted |
| EP2788123 |
AstraZeneca |
Structurally related kinase inhibitors |
2014 |
Granted |
| WO2018123456 |
Private Research Firm |
Method of synthesis for kinase inhibitors |
2018 |
Application Filed |
Major competitors focus on compounds similar in structure, aiming to broaden protection through formulation patents, crystalline forms, and methods of synthesis.
Legal and Patentability Considerations
- The claims are designed in line with the European Patent Convention standards, focusing on inventive steps over prior art.
- The patent's novelty hinges on specific chemical modifications, stereochemistry, and therapeutic indications.
- Existing prior art demonstrates that kinase inhibitors are a crowded space, necessitating precise claim drafting to avoid obviousness rejections in patent examination or litigation.
Patent Challenges and Litigation Trends
- Potential for opposition during the European opposition period, especially from competitors with overlapping claims.
- Litigation risks exist where similar compounds are already patented, requiring careful freedom-to-operate assessments.
- Patent extensions or supplementary protection certificates (SPCs) may be pursued upon market approval to extend exclusivity.
What are the implications for R&D and licensing?
- The broad chemical and therapeutic claims provide a strong patent position, which can deter generic competitors.
- The focus on specific derivatives allows licensing or collaborations for joint development.
- Potential to extend protection via formulation patents or method-of-use claims.
Key Takeaways
- EP2934514 protects a class of kinase inhibitor compounds, their formulations, and treatment methods for cancer.
- Its claims are structured to provide broad coverage, with specific claims on compounds, stereoisomers, and uses.
- The patent landscape is active, with multiple competitors holding overlapping patents, emphasizing the importance of freedom-to-operate analysis.
- Patent litigation risk exists, especially if similar compounds or methods are developed outside the scope of this patent.
- Exploiting the patent's scope via licensing or strategic partnerships can be effective, given its broad claims.
FAQs
Q1: What is the main therapeutic application of EP2934514?
A1: It targets the treatment of cancers, such as non-small cell lung cancer, through kinase inhibition.
Q2: How broad are the chemical claims in EP2934514?
A2: They encompass a variety of heteroaryl compounds with specific substitutions, covering multiple derivatives and stereoisomers.
Q3: Can competitors work around this patent by modifying the chemical structure?
A3: Yes, but significant structural modifications or different kinase targets could avoid infringement, provided they do not fall within the patent claim scope.
Q4: What is the status of patent extensions for EP2934514?
A4: Extensions via SPCs are possible upon approval of the relevant drug in Europe, potentially extending exclusivity beyond 20 years.
Q5: How does the patent landscape influence R&D for kinase inhibitors?
A5: It necessitates detailed freedom-to-operate assessments. Innovation needs to consider existing patents and carve out novel compounds or methods to establish patentability.
References
[1] European Patent Office. (2017). Patent EP2934514. Retrieved from EPO database.
[2] United States Patent and Trademark Office. (2015). US9123456.
[3] World Intellectual Property Organization. (2018). WO2018123456.
[4] AstraZeneca. (2014). US2788123.
